Arrowhead Pharmaceuticals' Capital Efficiency Outshines Among Peers

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) demonstrates a strong Return on Invested Capital (ROIC) of 20.84% compared to its Weighted Average Cost of Capital (WACC) of 9.83%, indicating efficient capital utilization.ACADIA Pharmaceuticals leads with the highest ROIC to WACC ratio among peers, suggesting superior efficiency and growth potential.Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company that focuses on developing medicines that treat intractable diseases by silencing the ...